Clarence Childress, MD
Infectious Disease · Glen Allen, VANPI 1902996549
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $524 and has fallen 96.3% since, to $19 in 2025.
Across 72 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$190
- Merck$183
- Novo Nordisk$160
- Viiv Healthcare Company$142
- Gilead$127
- Cranial Technologies, Inc$65
- plus $328 from 15 others
What the payments were for
- Food & beverage$1,13895%
- Education$575%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 10 | $190 |
| Merck | 13 | $183 |
| Novo Nordisk | 11 | $160 |
| Viiv Healthcare Company | 7 | $142 |
| Gilead | 7 | $127 |
| Cranial Technologies, Inc | 4 | $65 |
| Amgen | 3 | $53 |
| Boehringer Ingelheim | 2 | $40 |
| Ultragenyx Pharmaceutical Inc. | 2 | $35 |
| AstraZeneca | 2 | $28 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Abbott | 1 | $19 |
| Sobi, Inc | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
| GSK | 1 | $13 |
| Vyera Pharmaceuticals, LLC | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
| Pfizer | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
How this compares
$1,195 in reported general payments places this provider in the 75th percentile of 194 infectious disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 27 | $137,913 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 11 | $67,782 |
| OzempicSemaglutide | 42 | $58,239 |
| JanuviaSitagliptin Phosphate | 38 | $39,561 |
| JardianceEmpagliflozin | 19 | $34,602 |
| XareltoRivaroxaban | 17 | $11,786 |
| Atorvastatin Calcium | 239 | $1,843 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,802 |
| Azelastine Hcl | 31 | $1,759 |
| Levothyroxine Sodium | 106 | $1,450 |
| Gabapentin | 98 | $1,428 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $1,274 |
| Bupropion XlBupropion Hcl | 38 | $1,157 |
| Amlodipine Besylate | 181 | $937 |
| Fluticasone Propionate | 64 | $931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $127 | $137,91327 claims |
| Novo NordiskOzempic | $160 | $58,23942 claims |
| MerckJanuvia | $183 | $39,56138 claims |
| Boehringer IngelheimJardiance | $40 | $34,60219 claims |
| Johnson & JohnsonXarelto | $190 | $11,78617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 194 infectious disease providers in Virginia.
Other infectious disease in Glen Allen
- Christopher BettacchiMarion$243K
- Stephen WeinrothFairfax$157K
- William PetriCharlottesville$92K
- Michael IsonFalls Church$88K
- Valerie RiddleBumpass$83K
- Edward OldfieldNorfolk$81K
- William FurlongArlington$68K
- Frederick HaydenCharlottesville$61K
- David WheelerAnnandale$49K
- Amy MathersCharlottesville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.